ITP team GreenMark Biomedical Secures Third NIH Grant in 2025•ITP team RevBio® Receives First FDA Approval for a “Bone Glue” to Treat Extremity Fractures in a Clinical Trial•Insights on Engineering and Biofabrication of Early Cancer Models: ITP PI, Luiz Bertassoni's review published in Nature Reviews Bioengineering•ITP PI Luiz Bertassoni's work on early cancer detection and treatment featured in multiple outlets!•IADR Connect webinar, Phosphate, Proteins, and Patterning: Unraveling the Rules of Biomineralization•Biomaterial vaccines to make implanted orthopedic devices safer, Work by TRC Principal Investigator, David Mooney, highlighted and published in PNAS!•Congratulations to our TRC PI, Dr. David Mooney for winning the 2026 CMBE Award!•RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures•2nd Global Symposium on Artificial Intelligence in Dentistry - November 14-15, 2025•Congratulations to our ITP team, GreenMark Biomedical, on making the finalist list for 2025 dentech!

Innovator Networking series

November 17, 2023

Translational Research and Academic Entrepreneurship
Charles Hart, PhD
Executive Director,
UCSF Innovation Ventures
Catalyst Program

Basic Discovery Research to Translational Research
Gary D. Hammer, MD, PhD
Professor, University of Michigan
Director, Endocrine Oncology Program in Rogel Cancer Center